IntelliPlex™ Lung Cancer Panel - cfDNA

The IntelliPlex™ Lung Cancer Panel comprises NSCLC driver genes' DNA mutations and RNA fusion variants detection for use with samples extracted from NSCLC formalin-fixed paraffin-embedded tissues (FFPET) or liquid biopsies such as plasma. The cfDNA panel is a qualitative molecular assay for the detection of 74 DNA mutation hotspots in the KRAS, NRAS, PIK3CA, BRAF, EGFR, HER2, MEK1 and AKT1 genes from plasma samples in a single well by using PlexBio's core πCode technology.

FEATURES

Detect 8 driver genes, 74 mutation hotspots in one well test
Highly sensitive (0.1~2.32%) to detect low levels of mutant DNA
Only ≥10ng DNA sample required
Time to results in <6 hours for 96 samples per run (sample preparation included)

DOWNLOAD FILE

Broad Target Coverage

Detectable 8 driver genes,
74 DNA mutations in one well

Low Sample Input

Only 10ng DNA sample extracted from plasma required

High Sensitivity

Detects low levels of mutant DNA with a high sensitivity

Quick Turnaround Time

Sample to results in <6 hours with automated reporting

Overview

Related Products

Overview

While most lung cancer cases are sporadic rather than inherited, certain genes and even specific types of mutations are frequently observed in these cases. Traditional methods to identify certain mutations often rely on single-gene testing, which can be costly, time-consuming, and challenging due to the limited availability of clinical samples. The need for multiple, sequential tests increases the risk of insufficient sample volume, making it difficult to obtain a comprehensive molecular profile.

To address these limitations, the IntelliPlex™Lung Cancer Panel- cfDNA is an in-vitro molecular test based on πCode™technology and PlexBio's instrument platform to identify 74 DNA mutations in KRAS, NRAS, PIK3CA, BRAF, EGFR, HER2, MEK1 and AKT1 genes in NSCLC. πCode™ technology enables the multi-mutations detection in single-well with DNA samples derived from plasma. The kit provides all necessary optimized reagents for the sensitive detection of low levels of mutant DNA in a background of wild-type genomic DNA by simultaneous PCR amplification of target mutations.

Principle of πCode Multiplexing

BACK TO LIST